Volume 8 Number 1 2024
Eclampsia-An Emergent Condition: Pathophysiology, Diagnosis, Maternal-Fetal Outcomes, and Evidence-Based Management in Hypertensive Pregnancy Disorders
Khawla Mohammed Abdullah Al-Naim 1, Ahmed A Alsalami 1, Majed Suliman Alwalie 1, Abdullah Saleh Abdullah Almorshed 1, Abdullah Abdulrahman Mohammed Alrbian 1, Eissa Alhumaidi Almuterie 1, Abdulmajeed Muhayya Almutairi 1, Abdulrahman Abdullah Nazal Al-Anzi 1, Khalid Ali A Almzairie 1, Abdullah Saleh A Bin Muhaythif 1, Khalid Nafea Alharbi 1, Mohammed Hamad Aldossari 1, Mohammed Ahmed Ibrahim Alshaikhi 1, Hussain Muidh Hadi Alqahtani 1
Integrative Biomedical Research (Journal of Angiotherapy) 8 (6) 1-8 https://doi.org/10.25163/angiotherapy.8610330
Submitted: 29 April 2024 Revised: 11 June 2024 Published: 14 June 2024
Abstract
Background: Eclampsia, a life-threatening obstetric emergency characterized by seizures in pregnant or postpartum women with hypertensive disorders, remains a leading cause of maternal and perinatal morbidity and mortality. Despite advances in obstetric care, its pathophysiology—rooted in endothelial dysfunction, cerebral autoregulation failure, and blood-brain barrier disruption—is not fully understood. This review synthesizes current evidence on eclampsia’s etiology, diagnostic challenges, and evidence-based management to improve maternal-fetal outcomes. Methods: A comprehensive analysis of peer-reviewed studies, clinical guidelines, and epidemiological data was conducted, focusing on risk factors, diagnostic criteria, and therapeutic interventions. Results: Eclampsia affects 0.3% of pregnancies globally, with higher incidence in low-resource settings. Key risk factors include chronic hypertension, primigravidity, and obesity. Diagnosis hinges on clinical presentation (seizures ± hypertension/proteinuria), though 20% of cases lack classic preeclampsia features. Magnesium sulfate is the gold standard for seizure prophylaxis and treatment, reducing recurrence by 50%. Antihypertensives (labetalol, hydralazine, nifedipine) mitigate end-organ damage. Delivery is definitive therapy, with mode determined by maternal-fetal stability. Complications include HELLP syndrome (10–20% of cases), placental abruption, and long-term cardiovascular risks. Conclusion: Early recognition, prompt magnesium sulfate administration, and timely delivery are critical to improving outcomes. Multidisciplinary care, postpartum monitoring, and patient education on future pregnancy risks are essential. Future research should focus on biomarkers for early prediction and tailored therapies.
Keywords: Eclampsia, preeclampsia, hypertensive disorders of pregnancy, magnesium sulfate, maternal mortality, seizure prophylaxis.
References
American College of Obstetricians and Gynecologists. (2020). Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstetrics & Gynecology, 135(6), e237–e260.
Cameron, N. A., Everitt, I., Seegmiller, L. E., Yee, L. M., Grobman, W. A., & Khan, S. S. (2022). Trends in the incidence of new-onset hypertensive disorders of pregnancy among rural and urban areas in the United States, 2007 to 2019. Journal of the American Heart Association, 11(2), e023791.
Cífková, R. (2023). Hypertension in pregnancy: A diagnostic and therapeutic overview. High Blood Pressure & Cardiovascular Prevention, 30(4), 289–303. https://doi.org/10.1007/s40292-023-00556-y
Erez, O., Romero, R., Jung, E., Chaemsaithong, P., Bosco, M., Suksai, M., Gallo, D. M., & Gotsch, F. (2022). Preeclampsia and eclampsia: the conceptual evolution of a syndrome. American Journal of Obstetrics and Gynecology, 226(2S), S786–S803. https://doi.org/10.1016/j.ajog.2021.12.011
Fishel Bartal, M., & Sibai, B. M. (2022). Eclampsia in the 21st century. American Journal of Obstetrics and Gynecology, 226(2S), S1237–S1253.
Garovic, V. D., Dechend, R., Easterling, T., Karumanchi, S. A., McMurtry Baird, S., Magee, L. A., Rana, S., Vermunt, J. V., & August, P., American Heart Association Council on Hypertension; Council on the Kidney in Cardiovascular Disease, Kidney in Heart Disease Science Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; and Stroke Council. (2022). Hypertension in pregnancy: Diagnosis, blood pressure goals, and pharmacotherapy: A scientific statement from the American Heart Association. Hypertension, 79(2), e21–e41.
Harsono, A. A. H., Achmadi, A., Aldika Akbar, M. I., & Joewono, H. T. (2018). Recurrent seizures in 2 patients with magnesium sulfate-treated eclampsia at a secondary hospital. American Journal of Case Reports, 19, 1129–1134. https://doi.org/10.12659/AJCR.910631
Hauspurg, A., & Jeyabalan, A. (2022). Postpartum preeclampsia or eclampsia: Defining its place and management among the hypertensive disorders of pregnancy. American Journal of Obstetrics and Gynecology, 226(2S), S1211–S1221.
Jung, E., Romero, R., Yeo, L., Gomez-Lopez, N., Chaemsaithong, P., Jaovisidha, A., Gotsch, F., & Erez, O. (2022). The etiology of preeclampsia. American Journal of Obstetrics and Gynecology, 226(2S), S844–S866.
Lake, A. J., Al Khabbaz, A., & Keeney, R. (2017). Severe preeclampsia in the setting of myasthenia gravis. Case Reports in Obstetrics and Gynecology, 2017, 9204930. https://doi.org/10.1155/2017/9204930
Laskowska, M. (2023). Eclampsia: A critical pregnancy complication demanding enhanced maternal care: A review. Medical Science Monitor, 29, e939919.
Laskowska, M., & Bednarek, A. (2023). Optimizing delivery strategies in eclampsia: A comprehensive review on seizure management and birth methods. Medical Science Monitor, 29, e941709. https://doi.org/10.12659/MSM.941709
Ngene, N. C., & Moodley, J. (2024). Preventing maternal morbidity and mortality from preeclampsia and eclampsia particularly in low- and middle-income countries. Best Practice & Research Clinical Obstetrics & Gynaecology, 94, 102473.
Sinkey, R. G., Battarbee, A. N., Bello, N. A., Ives, C. W., Oparil, S., & Tita, A. T. N. (2020). Prevention, diagnosis, and management of hypertensive disorders of pregnancy: A comparison of international guidelines. Current Hypertension Reports, 22(9), 66.
Stefanovic, V. (2023). International Academy of Perinatal Medicine (IAPM) guidelines for screening, prediction, prevention and management of pre-eclampsia to reduce maternal mortality in developing countries. Journal of Perinatal Medicine, 51(2), 164–169. https://doi.org/10.1515/jpm-2022-0426
Sutton, A. L. M., Harper, L. M., & Tita, A. T. N. (2018). Hypertensive disorders in pregnancy. Obstetrics and Gynecology Clinics of North America, 45(2), 333–347. https://doi.org/10.1016/j.ogc.2018.01.007
Vousden, N., Lawley, E., Seed, P. T., Gidiri, M. F., Goudar, S., Sandall, J., Chappell, L. C., & Shennan, A. H., CRADLE Trial Collaborative Group. (2019). Incidence of eclampsia and related complications across 10 low- and middle-resource geographical regions: Secondary analysis of a cluster randomised controlled trial. PLoS Medicine, 16(3), e1002775.
Wheeler, S. M., Myers, S. O., Swamy, G. K., & Myers, E. R. (2022). Estimated prevalence of risk factors for preeclampsia among individuals giving birth in the US in 2019. JAMA Network Open, 5(1), e2142343. https://doi.org/10.1001/jamanetworkopen.2021.42343
Wilkerson, R. G., & Ogunbodede, A. C. (2019). Hypertensive disorders of pregnancy. Emergency Medicine Clinics of North America, 37(2), 301–316. https://doi.org/10.1016/j.emc.2019.01.006
Xiao, M. Z. X., Whitney, D., Guo, N., Bentley, J., Shaw, G. M., Druzin, M. L., & Butwick, A. J. (2022). Trends in eclampsia in the United States, 2009–2017: A population-based study. Journal of Hypertension, 40(3), 490–497.